Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients

Trimmomatic: a flexible trimmer for Illumina sequence data

Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · see citing works

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,380 · see citing works

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

Fitzmaurice, C., Allen, C., Barber, R. M., Barregård, L., Bhutta, Z. A., Brenner, H., Dicker, D., Chimed‐Ochir, O., Dandona, R., Dandona, L., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,229 · see citing works

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · see citing works

VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint

Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,822 · see citing works

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1× · see citing works

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1× · see citing works

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379 · see citing works

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377 · see citing works

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116 · see citing works

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589 · see citing works

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083 · see citing works

Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

Riely, G. J., Pao, W. J., Ceppa, D. P., Li, A. R., Rizvi, N. A., Venkatraman, E. S., Zakowski, M. F., Kris, M. G., Ladanyi, M., & Miller, V. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1846 · Cited by 730 · see citing works

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636 · see citing works

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583 · see citing works

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

Paik, P. K., Drilon, A. E. D. C., Fan, P., Yu, H. A., Rekhtman, N., Ginsberg, M. S., Borsu, L. A., Schultz, N. D., Berger, M. F., Rudin, C. M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1467 · Cited by 575 · see citing works

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

Ramalingam, S. S., Yang, J. C., Lee, C. K., Kurata, T., Kim, D., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7576 · Cited by 554 · see citing works

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Ercan, D., Choi, H. G., Yun, C.-H., Capelletti, M., Xie, T., Eck, M. J., Gray, N. S., & Jänne, P. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2789 · Cited by 368 · see citing works

Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

Tarón, M., Ichinose, Y., Rosell, R., Mok, T. S. K., Massutí, B., Zamora, L., Mate, J. L., Manegold, C., Ono, M., Queralt, C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2618 · Cited by 332 · see citing works

FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution

Newman, A. M., Bratman, S. V., Stehr, H., Lee, L. J., Liu, C. L., Diehn, M., & Alizadeh, A. A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu549 · Cited by 304 · see citing works

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., Chorley, C. G., Chuaqui, C., Cross, D. A. E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400822z · Cited by 279 · see citing works

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Lee, C. K., Davies, L. C., Wu, Y.-L. L. C., Mitsudomi, T., Inoue, A., Rosell, R., Zhou, C., Nakagawa, K., Thongprasert, S., Fukuoka, M., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw279 · Cited by 252 · see citing works

Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor

Yu, H. A., Tian, S. K., Drilon, A. E. D. C., Borsu, L. A., Riely, G. J., Arcila, M. E., & Ladanyi, M. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1066 · Cited by 245 · see citing works

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types

Shu, Y., Wu, X., Tong, X., Wang, X., Chang, Z., Mao, Y., Chen, X., Sun, J., Wang, Z., Hong, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00520-1 · Cited by 224 · see citing works

EGFR-mutated lung cancer: a paradigm of molecular oncology

Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010) · Oncotarget · doi:10.18632/oncotarget.186 · Cited by 197 · see citing works

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance

Minari, R., Bordi, P., & Tiseo, M. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.12.02 · Cited by 186 · see citing works

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC

Bersanelli, M., Minari, R., Bordi, P., Gnetti, L., Bozzetti, C., Squadrilli, A., Lagrasta, C. A. M., Bottarelli, L., Osipova, G., Capelletto, E., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.019 · Cited by 168 · see citing works

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig, S. J., & Shapiro, G. I. (2010) · PubMed · Cited by 155 · see citing works

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression

Ou, S.-H. I., Agarwal, N., & Ali, S. M. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.015 · Cited by 149 · see citing works

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer

Song, H., Jung, K. S., Yoo, K. H., Cho, J., Lee, J. Y., Lim, S. H., Kim, H. S., Sun, J., Lee, S., Ahn, J. S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.093 · Cited by 114 · see citing works

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613

Remón, J., Menis, J., Hasan, B., Peric, A., Maio, E. D., Novello, S., Reck, M., Berghmans, T., Wasąg, B., Besse, B., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.02.005 · Cited by 95 · see citing works

Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC

Chen, K., Zhou, F., Shen, W., Jiang, T., Wu, X., Tong, X., Shao, Y. W., Qin, S., & Zhou, C. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.024 · Cited by 89 · see citing works

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

Sullivan, I., & Planchard, D. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816670498 · Cited by 65 · see citing works

Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations

Caparica, R., Yen, C. T., Coudry, R. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.116 · Cited by 64 · see citing works

Epidermal growth factor receptor lacking C‐terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor

Maegawa, M., Arao, T., Yokote, H., MATSUMOTO, K. Y., Kudo, K., Tanaka, K., Kaneda, H., Fujita, Y., Ito, F., & Nishio, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2008.01071.x · Cited by 14 · see citing works

MA 20.13 etDNA: Tumor-Derived DNA from Pleural Effusion Supernatant as a Promising Source for NGS-Based Mutation Profiling in Lung Cancer

Tong, L., Ding, N., Li, J., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.652 · Cited by 4 · see citing works

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung Cancer

Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3563 · Cited by 411 · see citing works

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC

Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1542 · Cited by 387 · see citing works

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Shah, K. N., Bhatt, R., Rotow, J., Rohrberg, J., Olivas, V., Wang, V. E., Hemmati, G., Martins, M. M., Maynard, A., Kuhn, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0264-7 · Cited by 286 · see citing works

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4589 · Cited by 177 · see citing works

Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy

Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88 · see citing works

<scp><i>NTRK</i></scp> fusion positive colorectal cancer is a unique subset of <scp>CRC</scp> with high <scp>TMB</scp> and microsatellite instability

Wang, H., Li, Z., Ou, Q., Wu, X., Nagasaka, M., Shao, Y., Ou, S. I., & Yang, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.4561 · Cited by 64 · see citing works

Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer

문대성, 장태원, Ok, C. H., 정만홍, 김도현, & 최인수 (2009) · The Korean Journal of Internal Medicine

Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.

Shao, Y., Lin, C., & Yang, C.-H. (2010) · PubMed · Cited by 13 · see citing works

Successful Treatment of Non-small Cell Lung Cancer with Gefitinib after Severe Erlotinib-related Hepatotoxicity

Kunimasa, K., Yoshioka, H., Iwasaku, M., et al. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.6285 · Cited by 26 · see citing works

Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment

Сонг, Zheng-bo, Yu, et al. (2011) · 中华医学杂志：英文版

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours

Janne, P. A. (2008) · Lung Cancer · doi:10.1016/s0169-5002(08)70099-0 · Cited by 86 · see citing works